Peptide Therapeutics: The Growing Hope for Metabolic Disorders
Mohali, Punjab, India, February 16, 2016 --(PR.com)-- Roots Analysis has announced the addition of “Peptide Therapeutics in Metabolic Disorders, 2016-2025” report to its portfolio. The report provides a comprehensive study on the current market landscape and the future outlook of the evolving pipeline of peptide therapeutics that are being developed specifically for metabolic disorders. It is worth highlighting that, in addition to oncology, metabolic disorders have significantly captured the attention of peptide therapeutics developers. So far, over 20 peptide based drugs for various metabolic diseases have been approved.
Sohina Arora, the principal analyst, said, “The market is currently characterized by a robust and opportunistic pipeline of products targeting various metabolic indications; over 40% of the drugs are in early stages of development. Some of the drugs in this space, including BYETTA® / BYDUREON® and Victoza®, have already achieved blockbuster status.”
Technologies designed to enhance the stability, increase the bioavailability and facilitate the effective delivery of peptides have acted as key enablers to the market’s growth. Specifically, technologies offering alternative routes of administration and sustained drug delivery are likely to significantly improve patient compliance.
Arora further stated that, “Diabetes, obesity, osteoporosis and acromegaly are the key metabolic indications being targeted. Peptide based drugs are also being developed for other lesser known metabolic indications including erythropoietic protoporphyria, HIV related lipodystrophy, homozygous familial hypercholesterolemia, achondroplasia, Cushing’s disease, hypercalcemia and growth hormone deficiency. Currently, GLP-1 analogues hold the maximum share in the market. Pharmaceutical companies are also focused on developing other novel peptide analogues.”
Amongst other things, the report covers:
-The current state of the market featuring the key players, developmental stages of pipeline products (both clinical/pre-clinical), route of administration and target indications.
-The innovative technology platforms and delivery systems being investigated to eliminate challenges associated peptide drug administration.
-Partnerships formed in the recent past, covering R&D collaborations, manufacturing agreements, license agreements and co-development & co-commercialization deals.
-Recently approved and mid/late stage peptide therapeutics, highlighting their developmental history, available formulations, associated patents, key clinical trials and results.
-The epidemiology and patient population for each key metabolic indication.
Overall, the peptide therapeutics market for metabolic disorders is expected to witness a steady growth rate over the coming decade and be worth over USD 10 billion by 2025. As expected, diabetes will account for a majority share. Ongoing technological developments and research in other metabolic disorders will fuel growth in the long term.
Who will benefit from this report?
The report is likely to benefit big and small pharma companies involved in the development of peptide therapeutics for metabolic diseases. In particular, you could benefit if you are an:
Investor
CXO level decision maker
R&D manager
Business Intelligence / Scientific analyst
Finance manager
Strategy head
For additional details, please visit http://www.rootsanalysis.com/reports/view_document/peptide-therapeutics-in-metabolic-disorders-2016-2025/118.html
or email sales@rootsanalysis.com
About Roots Analysis
Roots Analysis is a specialist market research company, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like us to help you with your growing business needs, get in touch at info@rootsanalysis.com
Sohina Arora, the principal analyst, said, “The market is currently characterized by a robust and opportunistic pipeline of products targeting various metabolic indications; over 40% of the drugs are in early stages of development. Some of the drugs in this space, including BYETTA® / BYDUREON® and Victoza®, have already achieved blockbuster status.”
Technologies designed to enhance the stability, increase the bioavailability and facilitate the effective delivery of peptides have acted as key enablers to the market’s growth. Specifically, technologies offering alternative routes of administration and sustained drug delivery are likely to significantly improve patient compliance.
Arora further stated that, “Diabetes, obesity, osteoporosis and acromegaly are the key metabolic indications being targeted. Peptide based drugs are also being developed for other lesser known metabolic indications including erythropoietic protoporphyria, HIV related lipodystrophy, homozygous familial hypercholesterolemia, achondroplasia, Cushing’s disease, hypercalcemia and growth hormone deficiency. Currently, GLP-1 analogues hold the maximum share in the market. Pharmaceutical companies are also focused on developing other novel peptide analogues.”
Amongst other things, the report covers:
-The current state of the market featuring the key players, developmental stages of pipeline products (both clinical/pre-clinical), route of administration and target indications.
-The innovative technology platforms and delivery systems being investigated to eliminate challenges associated peptide drug administration.
-Partnerships formed in the recent past, covering R&D collaborations, manufacturing agreements, license agreements and co-development & co-commercialization deals.
-Recently approved and mid/late stage peptide therapeutics, highlighting their developmental history, available formulations, associated patents, key clinical trials and results.
-The epidemiology and patient population for each key metabolic indication.
Overall, the peptide therapeutics market for metabolic disorders is expected to witness a steady growth rate over the coming decade and be worth over USD 10 billion by 2025. As expected, diabetes will account for a majority share. Ongoing technological developments and research in other metabolic disorders will fuel growth in the long term.
Who will benefit from this report?
The report is likely to benefit big and small pharma companies involved in the development of peptide therapeutics for metabolic diseases. In particular, you could benefit if you are an:
Investor
CXO level decision maker
R&D manager
Business Intelligence / Scientific analyst
Finance manager
Strategy head
For additional details, please visit http://www.rootsanalysis.com/reports/view_document/peptide-therapeutics-in-metabolic-disorders-2016-2025/118.html
or email sales@rootsanalysis.com
About Roots Analysis
Roots Analysis is a specialist market research company, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like us to help you with your growing business needs, get in touch at info@rootsanalysis.com
Contact
Roots Analysis
Gaurav Chaudhary
+1-604-595-4954
www.rootsanalysis.com
Gaurav Chaudhary
+1-604-595-4954
www.rootsanalysis.com
Contact
Categories